Rhythm Pharmaceuticals at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Rhythm Pharmaceuticals at ASHG 2026 in Montréal: 1 presentation (1 poster).

Organization	ASHG 2026 Attendance
Rhythm Pharmaceuticals Boston, Massachusetts	1 Bioinformatics Scientist
rhythmtx.com\|LinkedIn Public company~414 people Rhythm sells precision medicines for rare neuroendocrine diseases, including IMCIVREE for genetic and acquired hypothalamic obesity. It serves patients and healthcare providers. Won Japanese approval of IMCIVREE for acquired hypothalamic obesity, opening a new international market for its genetic obesity drug. › Won Japanese approval of IMCIVREE for acquired hypothalamic obesity, opening a new international market for its genetic obesity drug. 2026-08 · source Appointed Manher Joshi as chief medical officer, a leadership addition as it expands IMCIVREE into new indications and markets. 2026-08 · source Got UK approval expanded for IMCIVREE to cover acquired hypothalamic obesity, growing the drug's addressable patient population there. 2026-08 · source Source: company newsroom Q2 2026 product revenue $71.3M, up from $48.5M › 2026 operating-expense guidance is $363-397 million as it scales IMCIVREE commercially. · 2026-08-04 “"Net product revenues from global sales of IMCIVREE were $71.3 million for the second quarter of 2026." "as compared to $48.5 million for the second quarter of 2025." "Rhythm anticipates approximately $363 million to $397 million in Non-GAAP Operating Expenses."” Source: results release Currently hiring: 55 open roles › Source: careers page	Poster Wed Oct 21 2:30 pm Part of Mendelian Phenotypes Poster Wednesday Session Phenotyping algorithm identifies high probability BBS cases in carriers of variants of uncertain significance in the All of Us cohort Exhibit & Poster Hall · Board 1121W CiliopathiesElectronic health recordsGenotype-phenotype correlationsRare variants

Organization

ASHG 2026 Attendance

Rhythm Pharmaceuticals

Boston, Massachusetts

1 Bioinformatics Scientist

rhythmtx.com|LinkedIn

Public company~414 people

Rhythm sells precision medicines for rare neuroendocrine diseases, including IMCIVREE for genetic and acquired hypothalamic obesity. It serves patients and healthcare providers.

Won Japanese approval of IMCIVREE for acquired hypothalamic obesity, opening a new international market for its genetic obesity drug.

›

Won Japanese approval of IMCIVREE for acquired hypothalamic obesity, opening a new international market for its genetic obesity drug.

2026-08 · source

Appointed Manher Joshi as chief medical officer, a leadership addition as it expands IMCIVREE into new indications and markets.

2026-08 · source

Got UK approval expanded for IMCIVREE to cover acquired hypothalamic obesity, growing the drug's addressable patient population there.

2026-08 · source

Source: company newsroom

Q2 2026 product revenue $71.3M, up from $48.5M

›

2026 operating-expense guidance is $363-397 million as it scales IMCIVREE commercially. · 2026-08-04

“"Net product revenues from global sales of IMCIVREE were $71.3 million for the second quarter of 2026." "as compared to $48.5 million for the second quarter of 2025." "Rhythm anticipates approximately $363 million to $397 million in Non-GAAP Operating Expenses."”

Source: results release

Currently hiring: 55 open roles

›

Source: careers page

Poster

Wed Oct 21
2:30 pm

Part of Mendelian Phenotypes Poster Wednesday Session

Phenotyping algorithm identifies high probability BBS cases in carriers of variants of uncertain significance in the All of Us cohort

Exhibit & Poster Hall · Board 1121W

CiliopathiesElectronic health recordsGenotype-phenotype correlationsRare variants